## Analysis of Beta-lactam Resistance Mechanisms ### Correct Statements (Options A, B, C) **Option A — MRSA Resistance via PBP2a:** **High-Yield:** MRSA acquires the *mecA* gene encoding PBP2a (also called PBP2'), an altered penicillin-binding protein with markedly reduced affinity for virtually all beta-lactams. Crucially, PBP2a's reduced affinity extends to carbapenems as well — carbapenems do NOT reliably overcome MRSA resistance in clinical practice. MRSA is considered resistant to all beta-lactams including carbapenems (with the exception of the novel anti-MRSA cephalosporins ceftaroline and ceftobiprole). This statement is therefore TRUE. **Option B — CRE via Carbapenemases:** **Clinical Pearl:** Carbapenem-resistant Enterobacteriaceae (CRE) produce carbapenemases (e.g., KPC, NDM-1, OXA-48, VIM, IMP) — serine- or metallo-beta-lactamases capable of hydrolyzing carbapenems (meropenem, imipenem, ertapenem). This is the defining mechanism of CRE and represents a major nosocomial threat. This statement is TRUE. **Option C — Mechanism of Action of Beta-lactams:** **Key Point:** Beta-lactams are bactericidal agents that covalently bind to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity and preventing cross-linking of peptidoglycan strands. This leads to cell wall instability and bacterial lysis. This statement is TRUE. ### Incorrect Statement (Option D — THE ANSWER) **Warning:** Option D contains a critical factual error regarding ESBL-producing organisms and beta-lactam/beta-lactamase inhibitor combinations. While ESBL production is indeed a common resistance mechanism in Gram-negative bacteria (predominantly *Klebsiella pneumoniae* and *Escherichia coli*), the claim that **ESBL-producing organisms remain susceptible to beta-lactam/beta-lactamase inhibitor combinations is FALSE** for the following reasons: 1. **Clinical resistance despite in vitro susceptibility:** ESBL-producing organisms frequently demonstrate clinical resistance to beta-lactam/beta-lactamase inhibitor combinations (e.g., piperacillin-tazobactam) even when in vitro testing suggests susceptibility. This is known as the "inoculum effect." 2. **High inoculum effect:** At high bacterial loads (as seen in serious infections), the large quantity of ESBL enzyme overwhelms the inhibitor, rendering the combination ineffective clinically. 3. **Treatment guidelines:** Current IDSA and international guidelines recommend **carbapenems** as the drugs of choice for serious infections caused by ESBL-producing organisms — NOT beta-lactam/beta-lactamase inhibitor combinations. 4. **MERINO trial evidence:** The MERINO trial (2018) demonstrated that piperacillin-tazobactam was inferior to meropenem for definitive treatment of ESBL-producing bacteremia, with higher 30-day mortality in the piperacillin-tazobactam group. Therefore, Option D is FALSE because ESBL-producing organisms are NOT reliably susceptible to beta-lactam/beta-lactamase inhibitor combinations in clinical practice. ### Summary Table | Resistance Mechanism | Organism | Mechanism | Beta-lactam/Inhibitor Efficacy | Carbapenem Efficacy | |---|---|---|---|---| | ESBL | *E. coli*, *K. pneumoniae* | Enzymatic hydrolysis | ✗ Unreliable (inoculum effect) | ✓ Drug of choice | | AmpC | *Enterobacter*, *Citrobacter* | Enzymatic hydrolysis | ✗ Resistant | ✓ Effective | | PBP2a (MRSA) | *S. aureus* | Altered target | ✗ Resistant | ✗ Resistant (clinical) | | Carbapenemase (CRE) | *Enterobacteriaceae* | Enzymatic hydrolysis | ✗ Resistant | ✗ Resistant | [cite: KD Tripathi 8e Ch 52; Harrison's Principles of Internal Medicine 21e; MERINO Trial, NEJM 2018]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.